8-K: Kymera Therapeutics Advances Next-Generation IRAK4 Degrader KT-485 with Sanofi, Secures $20 Million Milestone

Kymera Therapeutics announced that its partner Sanofi will advance the next-generation IRAK4 degrader KT-485 into clinical studies, leading to a $20 million milestone payment and potential for up to $975 million in future milestones, while discontinuing development of KT-474.

Summary

• Kymera Therapeutics announced an update to its collaboration with Sanofi S.A. regarding the development of drug candidates targeting IRAK4 for immuno-inflammatory diseases.
• Sanofi has selected KT-485/SAR447971, an oral, highly potent, and selective IRAK4 degrader discovered by Kymera, to advance into clinical studies.
• KT-485 is expected to advance into Phase 1 testing next year, following extensive preclinical work supporting its robust development potential.
• Based on the planned development of KT-485, Sanofi will not advance KT-474.
• Sanofi has exercised its participation election right for the IRAK4 target under the existing collaboration agreement.
• Kymera achieved a $20 million milestone in the second quarter of 2025 related to preclinical activities associated with KT-485.
• Kymera is eligible to receive up to $975 million of potential clinical, regulatory, and commercial milestones related to KT-485, including an additional milestone upon the start of Phase 1 clinical testing.
• In preclinical testing, KT-485 demonstrated an improved target product profile compared to KT-474, with greater potency and selectivity and a generally improved overall profile.
• Kymera may opt-in to 50/50 development and profit share of KT-485 in the U.S. and is eligible for double-digit royalties.

Sentiment

Score: 8

Explanation: The announcement is highly positive, indicating significant progress in a key collaboration, validation of a next-generation drug candidate with an improved profile, and substantial near-term and potential long-term financial benefits, despite the discontinuation of an earlier candidate.

Positives

• Sanofi's decision to advance KT-485 into clinical studies validates Kymera's next-generation IRAK4 degrader.
• Kymera received a $20 million milestone payment in Q2 2025 for preclinical activities related to KT-485.
• The company is eligible for substantial future milestones, up to $975 million, including a payment upon Phase 1 initiation.
• KT-485 demonstrated an improved preclinical profile over KT-474, with increased selectivity and potency and a favorable safety profile.
• Kymera retains the option to opt-in for a 50/50 development and profit share of KT-485 in the U.S., offering significant upside potential.
• The collaboration with Sanofi, a major pharmaceutical company, provides strong backing and resources for the program.

Negatives

• Sanofi will not advance KT-474, indicating a discontinuation of the previous lead candidate for this target.

Risks

• The timing and anticipated results of current and future preclinical studies and clinical trials may differ from expectations.
• There is a risk of delays in any current and future preclinical studies or clinical trials or the development of Kymera Therapeutics drug candidates.
• Results of current preclinical studies and clinical trials may not be predictive of future results in connection with current or future preclinical and clinical trials, including for KT-474 and KT-485.
• Kymera Therapeutics' ability to successfully demonstrate the safety and efficacy of its drug candidates is not guaranteed.
• The timing and outcome of Kymera Therapeutics' planned interactions with regulatory authorities may not be favorable.
• Risks associated with obtaining, maintaining, and protecting intellectual property.
• Risks related to Kymera Therapeutics' relationships with its existing and future collaboration partners.
• The availability of funding sufficient for operating expenses and capital expenditure requirements is a factor.

Future Outlook

Kymera Therapeutics expects KT-485 to advance into Phase 1 clinical testing next year. The company is eligible for significant future milestone payments, totaling up to $975 million, as the program progresses through clinical, regulatory, and commercial stages. Kymera also has the option to opt-in for a 50/50 development and profit share of KT-485 in the U.S.

Management Comments

• Nello Mainolfi, PhD, Founder, President and CEO, Kymera Therapeutics, commented: "Sanofi's intention to advance KT-485 into clinical testing and to direct all collaboration resources to the next-generation IRAK4 degrader is a reflection of the molecule's compelling preclinical profile and of Sanofi's and Kymera's commitment to transform immunology treatment paradigms."
• Mainolfi also stated: "Both companies have a strong belief in and commitment to targeting the IRAK4 pathway with degraders that are functionally differentiated from small molecule inhibitors, and to bringing forward the best oral medicines to patients living with immunological diseases."

Industry Context

This announcement highlights the growing importance of targeted protein degradation (TPD) as a novel therapeutic modality, particularly in immunological diseases. IRAK4, a master regulator of innate immunity, is a key target in this space, and its complete degradation (impacting both kinase and scaffolding functions) offers a potentially broad and well-tolerated anti-inflammatory effect. The advancement of KT-485 by a major pharmaceutical partner like Sanofi underscores the industry's confidence in TPD and the potential of IRAK4 degradation to deliver oral drug alternatives to upstream biologics for various immune-inflammatory conditions.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to assess the results in the context of global benchmarks. It focuses on the internal comparison between KT-485 and KT-474, noting KT-485's improved potency and selectivity.

Stakeholder Impact

• Shareholders: Potential for increased share value due to the advancement of a promising drug candidate, significant milestone payments, and future revenue potential from the Sanofi collaboration.
• Employees: Continued and potentially expanded work on a key development program, reinforcing job security and growth opportunities.
• Customers/Patients: Potential for a new, improved oral therapeutic option for immuno-inflammatory diseases, addressing significant unmet medical needs.
• Sanofi (Partner): Strengthened collaboration and commitment to the IRAK4 target, with a focus on a more potent and selective candidate.
• Creditors: Improved financial outlook and potential for future revenue streams may enhance the company's creditworthiness.

Next Steps

• KT-485 is expected to advance into Phase 1 clinical testing next year.
• Kymera is eligible for an additional milestone payment upon the start of Phase 1 clinical testing for KT-485.
• Kymera is eligible for up to $975 million in potential clinical, regulatory, and commercial milestones related to KT-485.
• Kymera may opt-in to 50/50 development and profit share of KT-485 in the U.S.

Key Dates

Recommendation

Keywords

Kymera Therapeutics, Sanofi, IRAK4 degrader, KT-485, SAR447971, immuno-inflammatory diseases, targeted protein degradation, clinical-stage biopharmaceutical, milestone payment, Phase 1 clinical trial, drug development, biotechnology, preclinical studies